Abstract Number: 1646 • 2017 ACR/ARHP Annual Meeting
Cardiovascular disease in Systemic Lupus Erythematosus. The road to hell is paved with good intentions
Background/Purpose: Accurate diagnosis of cardiovascular involvement in systemic lupus erythematosus (SLE) remains challenging, because echocardiography (echo), the cornerstone tool used, has serious limitations. We hypothesized…Abstract Number: 1647 • 2017 ACR/ARHP Annual Meeting
A Lupus Low Disease Activity State Is Associated with Reduced Flare, Lower Organ Damage Accrual, and Better Quality of Life in Patients with Systemic Lupus Erythematosus
Background/Purpose: To identify the potential predictors of a lupus low disease activity state (LLDAS), and the relationship between LLDAS and disease flare, organ damage, and…Abstract Number: 1648 • 2017 ACR/ARHP Annual Meeting
Assessment of Outcome in Lupus Nephritis Patients: A Retrospective Analysis of a Single Center Cohort over 20 Years
Background/Purpose: Lupus Nephritis (LN) is a severe SLE manifestation, leading to a six-fold increased risk of death. This study aims to assess the outcome of…Abstract Number: 1649 • 2017 ACR/ARHP Annual Meeting
Sleep Disturbances in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Sleep disturbances (SD) are reported to be common in SLE, but relatively few studies have addressed the issue. We examined the frequency and severity…Abstract Number: 1650 • 2017 ACR/ARHP Annual Meeting
The Montreal Cognitive Assessment Questionnaire (MoCA): A Promising Screening Tool for Cognitive Dysfunction in SLE
Background/Purpose: Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations in SLE. However, the diagnosis is oftentimes delayed and occasionally overlooked because of the…Abstract Number: 1651 • 2017 ACR/ARHP Annual Meeting
Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Background/Purpose: Despite effectiveness and favourable safety profile, antimalarials have the potential to cause irreversible macular retinopathy and vision loss. Screening methods still vary among clinicians…Abstract Number: 1652 • 2017 ACR/ARHP Annual Meeting
Trajectories of Quality of Life in an Iception Cohort of Lupus Patients and Their Determinants
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease with varying disease activity levels and morbidities over time; this can affect patients’ health related quality…Abstract Number: 1653 • 2017 ACR/ARHP Annual Meeting
Factors Influencing on Health-Related Quality of Life in Female Systemic Lupus Erythematosus Patients with Fibromyalgia
Background/Purpose: Health-related quality of life (HRQoL) among systemic lupus erythematosus (SLE) patients is reduced, and fibromyalgia contribute to the decreased HRQoL. The objective of the…Abstract Number: 1654 • 2017 ACR/ARHP Annual Meeting
Predictive Factors According to Type of Infection in Systemic Lupus Erythematosus Patients: Data from a Multi-Ethnic, Multi-National, Latin-American Cohort
Background/Purpose: While infections are a one of the main causes of mortality in systemic lupus erythematosus (SLE), the type of infections and the factors predisposing…Abstract Number: 1655 • 2017 ACR/ARHP Annual Meeting
Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus
Background/Purpose: Bone marrow mesenchymal stromal cells (BM-MSCs) are multipotent stem cells that can differentiate into chondrocytes, osteoblasts and adipocytes. SLE has been implicated as a…Abstract Number: 1656 • 2017 ACR/ARHP Annual Meeting
Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Background/Purpose: Dendritic cells (DC) are the sentinel cells of the immune system that potently activate T-cells, making them important players in the pathophysiology of systemic…Abstract Number: 1657 • 2017 ACR/ARHP Annual Meeting
SLE Patients with Active Interferon Pathways Showed More Systemic Disease Involvement Than Patients with Inactive Interferon Pathways
Background/Purpose : Systemic Lupus Erythematosus (SLE) is a clinically diverse disease with a complicated pathophysiology highlighted in part by interferon (IFN) pathway dysregulation. Recent studies…Abstract Number: 1658 • 2017 ACR/ARHP Annual Meeting
Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways
Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and…Abstract Number: 1659 • 2017 ACR/ARHP Annual Meeting
Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis
Background/Purpose: Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. Systemic lupus erythematosus (SLE) is a common autoimmune…Abstract Number: 1660 • 2017 ACR/ARHP Annual Meeting
Prolactin Induces an Interferon Signature in Monocytes and Drives IRF1-HAT Interactions
Background/Purpose: Epigenetic changes in systemic lupus erythematosus (SLE) offer a potential explanation for the chronicity of disease. We previously found that interferon regulatory factor-1(IRF1) binding…
ACR Meeting Abstracts